Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients

Background: Therapy monitoring of cancer treatment by contrast-enhanced CT (CECT), applying response evaluation criteria in solid tumors criteria version 1. 1 (RECIST 1.1) is less suitable for neuroendocrine tumors (NETs) which, when responding, tend to show stabilization rather than shrinkage. New...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Oncol
Hoofdauteurs: Pettersson, Olof, Fröss-Baron, Katarzyna, Crona, Joakim, Sundin, Anders
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2020
Onderwerpen:
Oncology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7047407/
https://ncbi.nlm.nih.gov/pubmed/32154181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00193
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items